ERG-driven EZH2 upregulation promotes epigenetic reprogramming and the activation of oncogenic pathways, including IGFR, MEK, WNT, NFκB, and PI3K/AKT, that facilitate tumor progression and metastasis (52, 53). The gene discussed is EZH2; the disease is neoplasm.